医学
射血分数
危险分层
内科学
心力衰竭
二尖瓣反流
观察研究
心脏病学
临床终点
临床试验
作者
Gregor Heitzinger,Georg Spinka,S Prausmueller,N Pavo,Varius Dannenberg,Carolina Donà,Andreas Kammerlander,Christian Nitsche,Stefan Kastl,Guido Strunk,M Huelsmann,Raphaël Rosenhek,Christian Hengstenberg,P Bartko,Georg Goliasch
标识
DOI:10.1093/eurheartj/ehac544.1643
摘要
Abstract Background Mitral regurgitation secondary to heart failure (sMR) has considerable impact on quality of life, heart failure (HF) rehospitalizations and mortality. A diverse burden of comorbidities suggests multifaceted aspects of individual risks. This risk-spectrum has never been studied but is essential to understand disease trajectories. Objectives To provide a comprehensive and structured decision-tree-like approach to risk-stratification in patients with severe sMR. Methods This large-scale, long-term observational study included 1317 patients with severe sMR from the entire HF spectrum (preserved, mid-range and reduced ejection fraction). Primary endpoint was all-cause mortality and survival tree analysis, a supervised learning technique, was applied to identify patient subgroups with excessive risk of mortality (Figure 1). Results Eight distinct subgroups that differed significantly in long-term survival were identified (Figure 2). Subgroup 7, characterized by younger age (≤66), higher hemoglobin (>12.7 g/dl) and higher albumin levels (>40.6 g/l) had the best survival. In contrast, subgroup 5 displayed a 20-fold risk of mortality (HR 95% CI: 20.38 ([0.78–38.52]), P<0.001) and presented with older age (>68 years) and low serum albumin (≤40.6 g/l) and higher NT-proBNP levels (≥9750 pg/ml). Results were consistent in internal and temporal validation. Conclusion Supervised machine learning reveals an unexpected heterogeneity in the sMR risk-spectrum, indicating the clinical challenges tied to severe sMR. A decision-tree-like model can guide through the risk spectrum and provide tailored risk-stratification. This structured approach provides the foundation to generate hypotheses towards improved therapeutic strategies and optimized patient care. Funding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Austrian Science Fund
科研通智能强力驱动
Strongly Powered by AbleSci AI